EE03527B1 - Tsükloalkaanindool- ja -asaindoolderivaadid, nende valmistamismeetod, kasutamine ravimite valmistamiseks, nimetatud derivaate sisaldavad ravimid ning karboksüülhapped kui vaheühendid nimetatud tsükloalkaanindool- ja -asaindoolderivaatide valmistamise - Google Patents

Tsükloalkaanindool- ja -asaindoolderivaadid, nende valmistamismeetod, kasutamine ravimite valmistamiseks, nimetatud derivaate sisaldavad ravimid ning karboksüülhapped kui vaheühendid nimetatud tsükloalkaanindool- ja -asaindoolderivaatide valmistamise

Info

Publication number
EE03527B1
EE03527B1 EE9500071A EE9500071A EE03527B1 EE 03527 B1 EE03527 B1 EE 03527B1 EE 9500071 A EE9500071 A EE 9500071A EE 9500071 A EE9500071 A EE 9500071A EE 03527 B1 EE03527 B1 EE 03527B1
Authority
EE
Estonia
Prior art keywords
indole
opt
derivatives
substd
alkyl
Prior art date
Application number
EE9500071A
Other languages
English (en)
Other versions
EE9500071A (et
Inventor
M�ller Ulrich
Connell Richard
Goldmann Siegfried
Gr�tzmann Rudi
Beuck Martin
Bischoff Hilmar
Denzer Dirk
Domdey-Bette Anke
Wohlfeil Stefan
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of EE9500071A publication Critical patent/EE9500071A/et
Publication of EE03527B1 publication Critical patent/EE03527B1/et

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
    • C07D219/02—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with only hydrogen, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EE9500071A 1994-10-04 1995-10-03 Tsükloalkaanindool- ja -asaindoolderivaadid, nende valmistamismeetod, kasutamine ravimite valmistamiseks, nimetatud derivaate sisaldavad ravimid ning karboksüülhapped kui vaheühendid nimetatud tsükloalkaanindool- ja -asaindoolderivaatide valmistamise EE03527B1 (et)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4435477A DE4435477A1 (de) 1994-10-04 1994-10-04 Cycloalkano-indol- und -azaindol-derivate

Publications (2)

Publication Number Publication Date
EE9500071A EE9500071A (et) 1996-04-15
EE03527B1 true EE03527B1 (et) 2001-10-15

Family

ID=6529939

Family Applications (1)

Application Number Title Priority Date Filing Date
EE9500071A EE03527B1 (et) 1994-10-04 1995-10-03 Tsükloalkaanindool- ja -asaindoolderivaadid, nende valmistamismeetod, kasutamine ravimite valmistamiseks, nimetatud derivaate sisaldavad ravimid ning karboksüülhapped kui vaheühendid nimetatud tsükloalkaanindool- ja -asaindoolderivaatide valmistamise

Country Status (36)

Country Link
US (6) US5684014A (et)
EP (1) EP0705831B1 (et)
JP (1) JP3901234B2 (et)
KR (1) KR100355986B1 (et)
CN (2) CN1050605C (et)
AT (1) ATE255580T1 (et)
AU (1) AU700609B2 (et)
CA (1) CA2159546C (et)
CZ (1) CZ291348B6 (et)
DE (2) DE4435477A1 (et)
DK (1) DK0705831T3 (et)
DZ (1) DZ1934A1 (et)
EE (1) EE03527B1 (et)
ES (1) ES2211890T3 (et)
FI (2) FI113048B (et)
HK (1) HK1005139A1 (et)
HN (1) HN1995009160A (et)
HR (1) HRP950505B1 (et)
HU (1) HU225052B1 (et)
IL (3) IL129641A (et)
MA (1) MA23683A1 (et)
MY (1) MY117282A (et)
NO (1) NO305365B1 (et)
NZ (1) NZ280130A (et)
PH (1) PH31400A (et)
PL (1) PL183154B1 (et)
PT (1) PT705831E (et)
RU (1) RU2157803C2 (et)
SG (1) SG63528A1 (et)
SI (1) SI0705831T1 (et)
SK (1) SK284260B6 (et)
SV (1) SV1995000062A (et)
TN (1) TNSN95098A1 (et)
TW (1) TW448175B (et)
UA (1) UA44700C2 (et)
ZA (1) ZA958297B (et)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4435477A1 (de) 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
DE19525028A1 (de) * 1995-07-10 1997-01-16 Bayer Ag Amide und Sulfonamide von heterocyclisch substituierten Benzylaminen
DE19613549A1 (de) * 1996-04-04 1997-10-09 Bayer Ag Verfahren zur Herstellung von enantiomerenreinen Cycloalkano-indol- und azaindol-carbonsäuren und deren aktivierte Derivate
US6774236B1 (en) 1996-04-04 2004-08-10 Bayer Aktiengesellschaft Process for the preparation of enantiomerically pure cycloalkano-indol -and azaindol -and pyrimido [1,2A]indolcarbocyclic acids and their activated derivatives
DE19619950A1 (de) 1996-04-17 1997-10-23 Bayer Ag Heterocyclisch-substituierte Phenylglycinolamide
EP0802192A1 (de) * 1996-04-17 1997-10-22 Bayer Ag Heterocyclisch-substituierte Phenylglycinolamide mit antiatherosklerotischer Wirkung und Verfahren zu ihrer Herstellung
DE19615119A1 (de) 1996-04-17 1997-10-23 Bayer Ag Neue Arylessigsäureamide
DE19615265A1 (de) * 1996-04-18 1997-12-04 Bayer Ag Neue Pyridazino-, Pyrimido-, Pyrazino- und Triazino-indole
EA003277B1 (ru) * 1998-05-01 2003-04-24 Эли Лилли Энд Компани СЛОЖНЫЙ ЭФИР-ИНГИБИТОР sPLA2
ES2213984T3 (es) 1998-10-30 2004-09-01 Eli Lilly And Company Derivados de azaindol y su uso como agentes antitrombicos.
WO2000071502A1 (fr) * 1999-05-25 2000-11-30 Yamanouchi Pharmaceutical Co., Ltd. Derives d'hydrazide
DE19929065A1 (de) * 1999-06-25 2000-12-28 Bayer Ag Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
DE19934610A1 (de) * 1999-07-23 2001-01-25 Bayer Ag Schnellfreisetzende Extrudate und Verfahren zu ihrer Herstellung sowie daraus erhältliche Zubereitungen
EP1134221A1 (en) * 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Substituted beta-carbolines as lkB kinase inhibitors
CA2402549A1 (en) * 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines
AU2001244635A1 (en) * 2000-03-30 2001-10-15 Yamanouchi Pharmaceutical Co..Ltd. Hydrazide derivatives
DE10030375A1 (de) * 2000-06-21 2002-01-03 Bayer Ag Verwendung von MTP-Inhibitoren zur Senkung von ppTRL
NZ527163A (en) * 2001-01-31 2006-02-24 Synaptic Pharma Corp Use of GAL3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
SG165154A1 (en) * 2002-02-28 2010-10-28 Japan Tobacco Inc Ester compound and medical use thereof
MXPA04011930A (es) * 2002-05-31 2005-03-31 Yamanouchi Pharma Co Ltd Derivados de tetrahidropirano.
WO2004063156A1 (en) * 2003-01-08 2004-07-29 Biovitrum Ab Novel indole derivates as fabp-4 inhibitors
WO2005051382A1 (ja) * 2003-11-28 2005-06-09 Astellas Pharma Inc. 脂質低下作用増強剤
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
JP5697296B2 (ja) 2004-03-05 2015-04-08 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 高脂血症および高コレステロール血症に関連する障害または疾患を、副作用を最小限にしつつ処置するための方法
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
AU2005230397B2 (en) * 2004-04-09 2010-04-08 Elanco Animal Health Ireland Limited Intermittent dosing regimen for the treatment of overweight with MTP-inhibitors
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
US20060030623A1 (en) * 2004-07-16 2006-02-09 Noboru Furukawa Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis
FR2873694B1 (fr) * 2004-07-27 2006-12-08 Merck Sante Soc Par Actions Si Nouveaux aza-indoles inhibiteurs de la mtp et apob
US8101774B2 (en) * 2004-10-18 2012-01-24 Japan Tobacco Inc. Ester derivatives and medicinal use thereof
AU2005297923B2 (en) * 2004-10-25 2010-12-23 Japan Tobacco Inc. Solid medicinal preparation improved in solubility and stability and process for producing the same
PA8660701A1 (es) 2005-02-04 2006-09-22 Pfizer Prod Inc Agonistas de pyy y sus usos
WO2006129193A2 (en) * 2005-05-27 2006-12-07 Pfizer Products Inc. Combination of a cannabinoid-1- receptor-antagonist and a microsomal triglyceride transfer protein inhibitor for treating obesity or mainataining weight loss
CA2617654A1 (en) * 2005-08-04 2007-02-08 Pfizer Limited Piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds
EP1951224A2 (en) * 2005-10-18 2008-08-06 Aegerion Pharmaceuticals Methods for treating disorders associated with hyperlipidemia in a mammal
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
US8138188B2 (en) * 2006-02-23 2012-03-20 Pfizer Inc. Melanocortin type 4 receptor agonist piperidinoylpyrrolidines
US8383660B2 (en) 2006-03-10 2013-02-26 Pfizer Inc. Dibenzyl amine compounds and derivatives
US20080051427A1 (en) * 2006-05-18 2008-02-28 Fritz Schuckler Pharmaceutical Compositions and Methods of Using Same
CA2669311C (en) 2006-11-13 2011-09-20 Pfizer Products Inc. Diaryl, dipyridinyl and aryl-pyridinyl derivatives and uses thereof
ES2382009T3 (es) 2006-12-01 2012-06-04 Bristol-Myers Squibb Company Derivados de N-((3-bencil)-2,2-(bis-fenil-)-propan-1-amina como inhibidores de CETP para el tratamiento de aterosclerosis y enfermedades cardiovasculares
US20080161279A1 (en) * 2006-12-21 2008-07-03 Wisler Gerald L Methods of Treating Obesity
RU2338745C1 (ru) * 2007-03-21 2008-11-20 Андрей Александрович Иващенко ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
WO2008124384A2 (en) * 2007-04-03 2008-10-16 Aegerion Pharmaceuticals, Inc. Combinations of mtp inhibitors with cholesterol absorption inhibitors or interferon for treating hepatitis c
CA2731897C (en) * 2008-08-06 2013-07-02 Pfizer Limited Diazepine and diazocane compounds as mc4 agonists
CN113416187A (zh) 2013-03-14 2021-09-21 奥斯特克有限公司 促进骨生长的烷基胺骆驼蓬碱衍生物
JP6782227B2 (ja) * 2014-09-05 2020-11-11 ザ・ジョンズ・ホプキンス・ユニバーシティー ＣａＭＫＩＩ阻害剤及びその使用
CN108218862B (zh) * 2018-02-07 2020-06-23 贵州医科大学 α-卡波林类衍生物在制备抗心肌缺氧复氧损伤药物中的应用
CN110467560A (zh) * 2018-05-09 2019-11-19 深圳微芯生物科技股份有限公司 一种苯基氨基丙酸钠衍生物、其制备方法和应用
SG11202101151SA (en) 2018-08-14 2021-03-30 Osteoqc Inc Pyrrolo - dipyridine compounds
MX2021001710A (es) 2018-08-14 2021-06-08 Osteoqc Inc Compuestos de fluoro ?-carbolina.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH501623A (de) * 1967-12-18 1971-01-15 Ruetgerswerke Ag Verfahren zur Herstellung von 2-Chlorpyridin und seinen Derivaten
US4808608A (en) * 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
ATE61047T1 (de) * 1986-01-23 1991-03-15 Merck Frosst Canada Inc Tetrahydrocarbazol-1-alkansaeuren.
US4940719A (en) * 1986-03-27 1990-07-10 Merck Frosst Canada, Inc. Tetrahydrocarbazole esters, pharmaceutical compositions and use
CA1326030C (en) * 1987-07-21 1994-01-11 John W. Gillard Cyclohept[b]indolealkanoic acids
US4775680A (en) * 1987-07-21 1988-10-04 Merck & Co., Inc. Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
GB9101375D0 (en) * 1991-01-22 1991-03-06 Erba Carlo Spa N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole
DE4112533A1 (de) * 1991-04-17 1992-10-22 Bayer Ag Verfahren zur herstellung von enantiomerenreinen substituierten (chinolin-2-yl-methoxy)phenyl-essigsaeuren
DE4200954A1 (de) 1991-04-26 1992-10-29 Bayer Ag Heterocyclisch substituierte phenylessigsaeurederivate
DE4308788A1 (de) * 1993-03-18 1994-09-22 Bayer Ag Hetero-tricyclisch-substituierte Phenyl-cyclohexan-carbonsäurederivate
DE4435477A1 (de) * 1994-10-04 1996-04-11 Bayer Ag Cycloalkano-indol- und -azaindol-derivate
DE19613549A1 (de) 1996-04-04 1997-10-09 Bayer Ag Verfahren zur Herstellung von enantiomerenreinen Cycloalkano-indol- und azaindol-carbonsäuren und deren aktivierte Derivate
DE19615119A1 (de) * 1996-04-17 1997-10-23 Bayer Ag Neue Arylessigsäureamide

Also Published As

Publication number Publication date
DZ1934A1 (fr) 2002-02-17
CA2159546C (en) 2010-12-14
TW448175B (en) 2001-08-01
JPH08225526A (ja) 1996-09-03
SK123995A3 (en) 1996-06-05
HN1995009160A (es) 2000-04-24
SI0705831T1 (en) 2004-02-29
MA23683A1 (fr) 1996-07-01
CN1050605C (zh) 2000-03-22
US20020055635A1 (en) 2002-05-09
EE9500071A (et) 1996-04-15
HU9502891D0 (en) 1995-11-28
CN1183111C (zh) 2005-01-05
HRP950505B1 (en) 2002-04-30
US20020147209A1 (en) 2002-10-10
FI20002693A (fi) 2000-12-08
AU3292095A (en) 1996-04-18
MY117282A (en) 2004-06-30
NO305365B1 (no) 1999-05-18
IL115493A0 (en) 1996-01-19
ATE255580T1 (de) 2003-12-15
DK0705831T3 (da) 2004-04-05
HU225052B1 (en) 2006-05-29
SG63528A1 (en) 1999-03-30
PH31400A (en) 1998-10-29
IL115493A (en) 1999-10-28
FI108791B (fi) 2002-03-28
EP0705831B1 (de) 2003-12-03
US20030149073A1 (en) 2003-08-07
ES2211890T3 (es) 2004-07-16
SK284260B6 (sk) 2004-12-01
ZA958297B (en) 1996-05-06
FI954681A0 (fi) 1995-10-02
PL183154B1 (pl) 2002-05-31
HK1005139A1 (en) 1998-12-24
AU700609B2 (en) 1999-01-07
US6245775B1 (en) 2001-06-12
CZ256795A3 (en) 1996-04-17
FI954681A (fi) 1996-04-05
HRP950505A2 (en) 1997-08-31
SV1995000062A (es) 1996-07-10
CN1224715A (zh) 1999-08-04
US6479503B2 (en) 2002-11-12
DE59510839D1 (de) 2004-01-15
FI113048B (fi) 2004-02-27
KR100355986B1 (ko) 2003-01-06
KR960014126A (ko) 1996-05-22
IL129641A (en) 2000-08-31
EP0705831A3 (de) 1997-01-22
PL310756A1 (en) 1996-04-15
CN1130631A (zh) 1996-09-11
US5684014A (en) 1997-11-04
NZ280130A (en) 1996-05-28
JP3901234B2 (ja) 2007-04-04
UA44700C2 (uk) 2002-03-15
TNSN95098A1 (fr) 1996-02-06
US6858622B2 (en) 2005-02-22
NO953930D0 (no) 1995-10-03
RU2157803C2 (ru) 2000-10-20
CA2159546A1 (en) 1996-04-05
CZ291348B6 (cs) 2003-02-12
DE4435477A1 (de) 1996-04-11
NO953930L (no) 1996-04-09
PT705831E (pt) 2004-04-30
IL129641A0 (en) 2000-02-29
EP0705831A2 (de) 1996-04-10
HUT73240A (en) 1996-07-29
US6265431B1 (en) 2001-07-24

Similar Documents

Publication Publication Date Title
EE03527B1 (et) Tsükloalkaanindool- ja -asaindoolderivaadid, nende valmistamismeetod, kasutamine ravimite valmistamiseks, nimetatud derivaate sisaldavad ravimid ning karboksüülhapped kui vaheühendid nimetatud tsükloalkaanindool- ja -asaindoolderivaatide valmistamise
HUT74939A (en) Imidazopyridine derivatives, process for their production and pharmaceutical compositions containing them
AU2819992A (en) Hiv protease inhibitors useful for the treatment of aids
FR2619111B1 (fr) Derives de (piperidinyl-4)methyl-2 tetrahydro-1,2,3,4 9h-pyrido (3,4-b) indole, leur preparation et leur application en therapeutique
NZ286756A (en) Indole, indazole, and benzisoxazole derivatives substituted in position 3' by 4-benzoylperhydroazepin-1-ylalkyl or 3-substituted pyrrolidin-1-ylalkyl
AU4538397A (en) New benzopyran compounds, process for preparing them and pharmaceutical compositions containing them
ATE73123T1 (de) Neue 3,5-dihydroxycarbonsaeuren und deren derivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte.
ES8604232A1 (es) Un procedimiento para la preparacion de derivados de penicilina
HUP9801404A2 (hu) Daganatellenes hatású gyógyszerkészítmény

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20021231

KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

KB4A Valid patent at the end of a year

Effective date: 20061231

KB4A Valid patent at the end of a year

Effective date: 20071231

KB4A Valid patent at the end of a year

Effective date: 20081231

KB4A Valid patent at the end of a year

Effective date: 20091231

MM4A Lapsed by not paying the annual fees

Effective date: 20091003